Tags

Type your tag names separated by a space and hit enter

A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
J Med Virol. 2020 06; 92(6):556-563.JM

Abstract

In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19.

Authors+Show Affiliations

Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China. The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou, Zhejiang, China. Peking University International Hospital, Beijing, China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Systematic Review

Language

eng

PubMed ID

32104907

Citation

Yao, Tian-Tian, et al. "A Systematic Review of Lopinavir Therapy for SARS Coronavirus and MERS coronavirus-A Possible Reference for Coronavirus Disease-19 Treatment Option." Journal of Medical Virology, vol. 92, no. 6, 2020, pp. 556-563.
Yao TT, Qian JD, Zhu WY, et al. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020;92(6):556-563.
Yao, T. T., Qian, J. D., Zhu, W. Y., Wang, Y., & Wang, G. Q. (2020). A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. Journal of Medical Virology, 92(6), 556-563. https://doi.org/10.1002/jmv.25729
Yao TT, et al. A Systematic Review of Lopinavir Therapy for SARS Coronavirus and MERS coronavirus-A Possible Reference for Coronavirus Disease-19 Treatment Option. J Med Virol. 2020;92(6):556-563. PubMed PMID: 32104907.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. AU - Yao,Tian-Tian, AU - Qian,Jian-Dan, AU - Zhu,Wen-Yan, AU - Wang,Yan, AU - Wang,Gui-Qiang, Y1 - 2020/03/12/ PY - 2020/02/13/received PY - 2020/02/24/accepted PY - 2020/2/28/pubmed PY - 2020/7/1/medline PY - 2020/2/28/entrez KW - COVID-19 KW - MERS KW - SARS KW - coronavirus KW - lopinavir SP - 556 EP - 563 JF - Journal of medical virology JO - J Med Virol VL - 92 IS - 6 N2 - In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19. SN - 1096-9071 UR - https://www.unboundmedicine.com/medline/citation/32104907/A_systematic_review_of_lopinavir_therapy_for_SARS_coronavirus_and_MERS_coronavirus_A_possible_reference_for_coronavirus_disease_19_treatment_option_ L2 - https://doi.org/10.1002/jmv.25729 DB - PRIME DP - Unbound Medicine ER -